Search results
Results from the WOW.Com Content Network
Zicam was invented and developed by Charles B. Hensley and Robert Steven Davidson in the mid 1990s, working on the ICAM-1 synthesis success of the Hafdua Laboratory in Haifa, Israel, under the direction of Mich Segal and Avram Satz, and is produced, marketed and sold by Zicam, LLC, a wholly owned subsidiary of Matrixx Initiatives, Inc., [5] [6 ...
Suvorexant is used for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, in adults. [2] [6] At a dose of 15 to 20 mg and in terms of treatment–placebo difference, it reduces time to sleep onset by up to 10 minutes, reduces time awake after sleep onset by about 15 to 30 minutes, and increases total sleep time by about 10 to 20 minutes. [2]
Primary insomnia is a sleep disorder not attributable to a medical, psychiatric, or environmental cause. [127] There are three main types of primary insomnia. These include psychophysiological, idiopathic insomnia, and sleep state misperception (paradoxical insomnia). [ 124 ]
For premium support please call: 800-290-4726 more ways to reach us
A new study reveals a shocking potential cause for insomnia.
One of the important questions in sleep research is clearly defining the sleep state. This problem arises because sleep was traditionally defined as a state of consciousness and not as a physiological state, [14] [15] thus there was no clear definition of what minimum set of events constitute sleep and distinguish it from other states of partial or no consciousness.
Let’s talk about sleep. Sweet, glorious, elusive sleep. We’re willing to bet if you clicked on this story, you’re not getting enough of it. That sucks. But luckily, you can learn from the ...
Last year, for instance, Merck spent $96 million promoting Belsomra. The investment proved to be worth it. Analysts expect the drug to generate more than $300 million in sales this year and to overtake both Ambien and Lunesta as the top-selling insomnia medication sometime within the next decade.